IFPMA Announces Amgen as New Member Company

Washington DC, 10 November 2010 – The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Amgen has become its newest member company.

IFPMA Director General Eduardo Pisani said: “Amgen is a major force in the increasingly significant biotech sector and is therefore an important and welcome addition to the IFPMA. Amgen will provide us with new perspectives on emerging issues and, I hope, the IFPMA’s experience in dealing with global issues will be able to help Amgen as it expands its geographical presence.”

A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. Amgen’s headquarters are in Thousand Oaks, California, USA.

For general information on Amgen, please go to www.amgen.com. For details of the company’s corporate citizenship activities, please go to www.amgen.com/citizenship/overview.html.

(ends)
About the IFPMA:

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical industry, including the biotech and vaccine sectors. Its members comprise 26 leading international companies and 46 national and regional industry associations covering developed and developing countries. The industry’s R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal (www.ifpma.org/ClinicalTrials), the IFPMA’s Ethical Promotion online resource (www.ifpma.org/EthicalPromotion) and its Developing World Health Partnerships Directory (www.ifpma.org/HealthPartnerships) help make the industry’s activities more transparent. The IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For further information, please contact:

Guy Willis
Director of Communications
E-mail: g.willis@ifpma.org
Tel: +41 22 338 32 00
Fax: +41 22 338 32 99
Web: www.ifpma.org